EDITORIAL BOARD
Maurie Markman, MD
Cancer Treatment Centers of America
Drexel University College of Medicine
Philadelphia, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania
It has been well documented that the patients entered into most Phase III randomized trials, and particularly studies designed to achieve US regulatory approval of new antineoplastic drugs, are vastly different from individuals who are encountered in routine medical practice. The underrepresentation of older patients (>65-70 years of